Long-acting beta2-agonist monotherapy vs continued therapy with inhaled corticosteroids in patients with persistent asthma: a randomized controlled trial.

@article{Lazarus2001LongactingBM,
  title={Long-acting beta2-agonist monotherapy vs continued therapy with inhaled corticosteroids in patients with persistent asthma: a randomized controlled trial.},
  author={Stephen C. Lazarus and Homer A. Boushey and John V Fahy and Vernon M. Chinchilli and Robert F. Lemanske and Christine A. Sorkness and Monica Kraft and James E. Fish and Stephen P. Peters and Timothy John Craig and Jeffrey M Drazen and Jean G. Ford and Richard J. Martin and Elizabeth A Mauger and Sami A. Nachman and Joseph D. Spahn and Stanley J Szefler},
  journal={JAMA},
  year={2001},
  volume={285 20},
  pages={
          2583-93
        }
}
CONTEXT Long-acting beta(2)-agonists are prescribed for patients with persistent asthma and are sometimes used without inhaled corticosteroids (ICSs). No evidence exists, however, to support their use as monotherapy in adults with persistent asthma. OBJECTIVE To examine the effectiveness of salmeterol xinafoate, a long-acting beta(2)-agonist, as replacement therapy in patients whose asthma is well controlled by low-dose triamcinolone acetonide, an ICS. DESIGN AND SETTING A 28-week… CONTINUE READING
Highly Cited
This paper has 96 citations. REVIEW CITATIONS

Citations

Publications citing this paper.
Showing 1-10 of 101 citations

96 Citations

0510'02'05'09'13'17
Citations per Year
Semantic Scholar estimates that this publication has 96 citations based on the available data.

See our FAQ for additional information.